Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 October 2020 | Story Ruan Bruwer | Photo BackpagePix
Khanyisa Chawane, a Protea player, should be one of the stars for the Free State Crinums in the Telkom Netball League. She was the Player of the League in 2018.

Having to play 11 matches in so many days before the knockout stage will be a daunting task, but their fitness levels are up to standard, says the coach of the Free State netball team. Burta de Kock of KovsieSport will again guide the Free State Crinums in the Telkom Netball League, which will be taking place between 14 and 27 October in Bloemfontein.

All but one of the 12 members of the team are studying at the University of the Free State (UFS).

“Planning will be of the utmost importance to manage the load on the players. We also have four players (Rolene Streutker, Chanel Vrey, Boitumelo Mahloko, and Refiloe Nketsa) who will participate in the South African U21 team that will play five invitational matches during the competition,” said De Kock.

In previous years, the competition took place over four to six weeks, but now it had to be fitted into two weeks due to COVID-19.

“So, it will be a tall order to play so many matches, but an exciting challenge. I believe the hard work the players had put in during the lockdown period will bear fruit. They were exceptional and very determined to stay in shape.”

The Crinums won the first three years of the competition, but couldn’t reach the final in the following three years. Apart from the 11 Kovsies in the Crinums team, there are 9 current or former UFS students in other teams participating in the league. 

They are Zandré Smit, Bianca Pienaar, Dané Klopper, Arné Fourie, Bethenie du Raan (all Northern Cape Diamonds), Maryke Coetzee, Danelle van der Heever (both Mpumalanga Sunbirds), Rieze Straeuli (Western Cape Tornados), and Alicia Puren (KZN Kingdom Stars).

The Crinums team: Boitumelo Mahloko, Ané Retief, Jana Scholtz, Khanyisa Chawane, Lefébre Rademan (captain), Sikholiwe Mdletshe, Claudia van den Berg, Bianca de Wee, Rolene Streutker, Chanel Vrey, Lerato Chabwe, and Refiloe Nketsa.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept